Last reviewed · How we verify
6% Hydroxy Ethyl Starch
6% Hydroxy Ethyl Starch, marketed by Innogene Kalbiotech Pte. Ltd, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its unique mechanism of action for its primary indication. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | 6% Hydroxy Ethyl Starch |
|---|---|
| Also known as | Voluven |
| Sponsor | Innogene Kalbiotech Pte. Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
- Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery (PHASE3)
- The Stroke Volume Optimization of Goal Directed Fluid Therapy During Radical Cystectomy (NA)
- Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery
- Crystalloid Versus Hydroxyethyl Starch Trials (PHASE3)
- Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients (PHASE4)
- BaSES Trial: Basel Starch Evaluation in Sepsis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6% Hydroxy Ethyl Starch CI brief — competitive landscape report
- 6% Hydroxy Ethyl Starch updates RSS · CI watch RSS
- Innogene Kalbiotech Pte. Ltd portfolio CI